InflaRx N.V. Common Stock (IFRX) is a publicly traded Healthcare sector company. As of May 21, 2026, IFRX trades at $2.41 with a market cap of $368.23M and a P/E ratio of 0.00. IFRX moved +2.95% today. Year to date, IFRX is +114.03%; over the trailing twelve months it is +37.85%. Its 52-week range spans $0.71 to $2.95. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces IFRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
InflaRx closes $150 million equity offering: 75 million shares at $2 each: InflaRx completed a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share, generating gross proceeds of $150 million before underwriting discounts and expenses. The company plans to use net proceeds to advance its izicopan and vilobelimab pipeline programs, bolster working capital and fund general corporate activities.
| Metric | Value |
|---|---|
| Price | $2.41 |
| Market Cap | $368.23M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.95 |
| 52-Week Low | $0.71 |
| Volume | 255 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
6 analysts cover IFRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.